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Activation of peripheral blood CD4/ helper T lymphocytes establishes a permissive state for growth of HIV-1. Activated T
lymphocytes expressed increased sialidase (neuraminidase) activity and were hyposialylated. Treatment of freshly isolated
peripheral blood mononuclear cells (PBMCs) with microbial neuraminidase (NANase) or phytohemagglutinin (PHA) prior to
infection at low multiplicity with T cell line-adapted HIV-1IIIB resulted in production of large amounts of p24 antigen and reverse
transcriptase. In contrast, neither viral component was detected in the medium of mock-treated cells infected at a similar
multiplicity through 21 days in culture. The titer of a stock solution of HIV-1IIIB was 1.4 { 0.18 log10 greater in NANase-treated
PBMCs than in mock-treated cells; the titer was similarly raised 1.5 to 1.76 { 0.18 log10 in PHA-treated cells. Growth of the
primary isolate HIV-191/US/056 was also enhanced in NANase-treated PBMCs; the titer of a stock solution of HIV-191/US/056 was
1.0 { 0.16 log10 greater in NANase-treated PBMCs than in mock-treated cells 7 days after infection. No enhancement of viral
growth in PBMCs was detected when NANase was heat-inactivated or specifically inhibited with 2,3-dehydro-2-desoxy-N-
acetyl-neuraminic acid prior to use. Treatment of PBMCs with NANase did not alter the distribution of lymphocyte subsets
nor change the density of CD4 antigen per cell after 7 days in culture. Whereas PHA treatment of PBMCs was mitogenic,
pretreatment with NANase was not; the amount of [3H]thymidine incorporated into DNA and culture growth characteristics
were similar for NANase- and mock-treated cells. Thus, desialylation of PBMCs promoted a permissive state for growth of
HIV-1 without affecting the rate of DNA synthesis or relative number of target CD4/ cells. q 1997 Academic Press
INTRODUCTION in murine T cells incubated in a mixed lymphocyte reac-
tion (Taira and Nariuchi, 1988). A relative reduction in
Modulation of the sialic acid content of protein and
the sialic acid content of lymphocytic surface proteins
lipid moieties on the surface of T lymphocytes occurs
also occurs in processes other than cell activation, such
with changes in functional capacities of these cells (Fo-
as in HIV-infected CEM cells (Lefebvre et al., 1994a,b)gel et al., 1983; Hunig, 1983; Landolfi and Cook, 1986;
and in the Wiskott–Aldrich immunodeficiency syndromeStout et al., 1987; Takeda, 1987; Taira and Nariuchi,
(Remold-O’Donnell et al., 1984).1988). Activated antigen-responsive lymphocytes that ag-
Sialylated proteins on the surface of T lymphocytesgregated in vivo in germinal centers of lymph nodes were
have been implicated in ligand binding, cell–cell interac-hyposialylated in comparison to resting T cells (reviewed
tion, and cell activation. These sialoproteins, which arein Springer, 1990). Moreover, T cells activated in vitro
potential targets for endogenous sialidases, include leu-after exposure to the mitogenic lectin Con A had hyposia-
kosialin (CD43), common leukocyte antigen (CD45), classlylated class I molecules (Landolfi and Cook, 1986) and
I proteins, LFA-1, CD4 receptor, and the inositol 1,4,5-increased amounts of asialo-GM, a desialylated ganglio-
trisphosphate receptor (Landolfi and Cook, 1986; Takeda,side (Stout et al., 1987), when compared to untreated
1987; Carr et al., 1989; Cyster et al., 1991; Khan et al.,cells. The hyposialylation of these glycoconjugates may
1992; Lefebvre et al., 1994a,b). Although potential rolesbe due to the increased activity of endogenous sialidase
have been suggested for some of these proteins, thefound in Con A-activated T cells (Landolfi et al., 1985) or
relationship between extent of sialylation and these func-
tions awaits clarification.
1 To whom correspondence and reprint requests should be ad- Successful infection of peripheral blood CD4/ T lym-
dressed at Division of Retrovirology, Walter Reed Army Institute of
phocytes with HIV-1 occurred in vitro after activation ofResearch, Washington, DC 20307-5100. Fax: (301) 762-4177. E-mail:
cells with mitogenic agents such as PHA (Cullen andnstamatos@pasteur.hjf.org.
2 Present address: Center for Special Immunology, 1625 S.E. 3rd Greene, 1989; Gowda et al., 1989; Zack et al., 1990).
Ave., Suite 600, Fort Lauderdale, FL 33316. The cellular changes associated with activation which
3 Present address: Division of Infectious Diseases, Department of contributed to viral growth were not well defined, al-Medicine, University of Maryland School of Medicine and Program in
though DNA synthesis (Zack et al., 1990, 1992) and cyto-Oncology, 22 South Green St., Marlene and Stewart Greenebaum Can-
cer Center, Baltimore, MD 21201-1734. kine production (Kinter et al., 1995) appeared to be re-
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TABLE 1quired. We speculated that hyposialylation of glycoconju-
gates on the surface of PBMCs, as occurred during cell Pretreatment of PBMCs with Neuraminidase Enhances
activation, may have a role which facilitates infection of Susceptibility to Infection with HIV-1
freshly isolated cells by HIV-1. In this report, we show
Number of positive cultures afterthat NANase-treated PBMCs supported growth of both
HIV-1 pretreatment withT cell line-adapted and primary strains of HIV-1 after
inoculum
infection at low m.o.i. in the absence of lectin-induced TCID50 None PHA NANase
activation.
Expt I 50 2/2a 2/2 2/2
5 2/2 4/4 4/4
MATERIALS AND METHODS 1 0/8 5/8 4/8
Expt II 128 5/5 5/5 5/5
Isolation of PBMCs. PBMCs were isolated by leuko- 32 3/5 5/5 5/5
phoresis of blood from HIV-1- and Hepatitis B-seronega- 8 1/5 5/5 5/5
2 0/5 4/5 4/5tive donors followed by centrifugation over lymphocyte
0.5 0/5 2/5 0/5separation medium (LSM; Organon Teknika, Durham,
NC). Where indicated, PBMCs were further purified by
Note. PBMCs and monocyte-depleted PBMCs were treated with PHA
counterflow centrifugation/elutriation (Wahl et al., 1984) or NANase (1 U/ml), or were mock-treated, and were maintained in
to yield mononuclear cell preparations with 1% mono- culture as described under Materials and Methods. PBMCs were plated
at 2.5 1 105 cells/well and were infected with 50, 5, or 1 TCID50 of HIV-cyte contamination, determined by flow cytometry, and
1 in 0.25 ml of complete media (Experiment I). Alternatively, monocyte-95% viability, determined by trypan blue exclusion.
depleted PBMCs were plated at 1 1 105 cells/well and infected withPBMCs and monocyte-depleted PBMCs were stored in
serial fourfold dilutions of HIV-1 (Experiment II). Levels of p24 antigen
liquid nitrogen at 107 cells/ml in RPMI 1640 medium in culture fluids were determined by ELISA and data from Days 18
(GIBCO, Grand Island, NY) containing 20% heat-inacti- (Experiment I) and 14 (Experiment II) postinfection are shown. Virus-
producing cultures of PHA- and NANase-treated PBMCs infected withvated normal human serum (NHS; Intergen, Purchase,
1 TCID50 produced an average of 69 { 37 and 26 { 24.4 ng/ml of p24NY) and 10% DMSO. For experiments with PBMCs de-
antigen, respectively, on Day 18 postinfection. p24 levels  0.015 ng/scribed in this report, PBMCs from each donor were
ml indicated absence of productive infection. The titer of the inoculum
thawed and screened to select cells which incorporated was determined originally in PHA-treated cells.
an amount of [3H]thymidine during a 7-day period not a Number of wells positive for p24 Ag/number of wells sampled.
more than one to three times above the amount incorpo-
rated on Day 1 when grown in medium with 10% NHS in
the absence of recombinant human IL-2 (rhIL-2; Boeh- 1.0 mM for 10 min at room temperature prior to addition to
PBMCs. The cells were then treated with inhibited NAN-ringer-Mannheim, Indianapolis, IN). Cell viability after
thawing was 90% as determined by trypan blue exclu- ase as indicated above. The NANase stock was dis-
solved in RPMI 1640 with 10% NHS at 50 U/ml and wassion.
Pretreatment of PBMCs with PHA or NANase. For treat- stored at 0207.
HIV-1 infection of PBMCs. HTLV-IIIB/H9, an HIV strainment with PHA (Burroughs Wellcome, Research Triangle,
NC), cells were thawed and grown for 48 hr at 377 at 2 adapted to T cell lines, and 91/US/056, a primary isolate
of HIV-1, were obtained from the AIDS Research and1 106 cells/ml in RPMI 1640 medium containing 10%
NHS and PHA at 1 mg/ml. Medium was changed after Reference Reagent Program, NIAID, NIH, and were used
to infect the lymphocytes in 96-well microtiter plates.48 hr and the concentration of PHA was lowered to 0.5
mg/ml for an additional 24 hr incubation at 377 before When monocyte-depleted PBMCs were used, PHA-,
NANase-, and mock-treated cells at 1 1 105/well wereinfection with HIV-1. Alternatively, for treatment with
NANase (crystalline, type X, from Clostridium perfringens; incubated for 24 hr at 377 with serial fourfold dilutions of
HIV-1 (42 –48, 3 or 5 wells per virus dilution) in a finalSigma, St. Louis, MO), cells from the same donor were
thawed and grown for 18 hr in RPMI 1640 medium with volume of 60 ml of RPMI 1640 with 10% NHS and 10%
rhIL-2 (complete medium). After 24 hr, cells were washed10% NHS prior to treatment with microbial NANase or
for use as mock-treated cells. These cells were collected twice with 1 ml of complete medium to remove unab-
sorbed virus using a Biomek1000 automated workstation.by centrifugation and resuspended at 107 cells/ml for a
30-min treatment at 377 with 0 to 1 U/ml of NANase The washed cells were resuspended in 200 ml of com-
plete medium and dispensed into wells of new 96-wellimmediately prior to infection with HIV-1. PHA-, NANase-,
and mock-treated cells were collected, washed twice, U-bottom microtiter plates. Medium was replaced on
Days 4, 7, and 14 by removing one-half of its volumeresuspended in RPMI 1640 with 10% NHS, and dis-
pensed in 96-well microtiter plates (Costar). and adding an equal volume of fresh medium. To avoid
overcrowding of PHA-treated cells only, one-half of theseWhere indicated, NANase was specifically inhibited by
incubation with 2,3-dehydro-2-desoxy-N-acetyl-neurami- cells were removed on Day 4.
When unfractionated PBMCs were infected, 2.5 1 105nic acid (NeuAc2en; Boehringer-Mannheim) at 250 mM or
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cells/well were infected with 50, 5, and 1 TCID50 HIV-l [
3H]thymidine (6.7 Ci/mmol; New England Nuclear Corp.,
Wilmington, DE). Neuraminidase-pretreated cells were(four to eight wells/dilution) in 0.25 ml of complete me-
dium. One-half of the medium was replaced with fresh washed twice as described above prior to being dis-
pensed in complete medium. The method for treatmentmedium 24 hr postinfection and every 48 hr subse-
quently. with PHA was modified slightly from that described ear-
lier so as to synchronize the labeling of PHA-, NANase-,On indicated days, an aliquot of medium from each of
the replicate wells of the individual samples was assayed and mock-treated cells from the time of thawing the cells.
PHA-stimulated cells were dispensed in complete me-for p24 antigen content by ELISA (Coulter Immunology,
Hialeah, FL). Infected cells were maintained in culture for dium containing 1 mg/ml PHA, with the concentration
of PHA being reduced by one-half every other day by21–22 days. Viral titers were determined by a computer
program designed for calculating viral infectivity (Layne replacement of one-half of the culture medium with fresh
complete medium. Cells (five wells/condition) were la-et al., 1989; Spouge, 1992). The assay for reverse tran-
scriptase was kindly done by Dr. Monte S. Meltzer (Gen- beled for 6 hr on Days 1, 2, 3, 6, and 9 with 0.50 mCi
of [3H]thymidine/well, harvested with an automated celldelman et al., 1990).
Determination of total cell-associated sialic acid. harvester (Skatron, Lier, Norway), and assayed for [3H]-
thymidine incorporation using a LKB Beta Plate systemPBMCs which were PHA-, NANase-, or mock-treated
were washed three times in cold RPMI before exposure (Gaithersburg, MD). A replicate plate was used for count-
ing cell number and determining viability (five wells/con-of pelleted cells to 0.1 M H2SO4 at 807 for 1 hr to release
cell-associated sialic acid. Free sialic acid was mea- dition) using trypan blue dye exclusion.
sured by the Warren assay (Warren, 1959).
Determination of cellular sialidase activity. PBMCs in RESULTS
complete medium were incubated for 48 hr at 377 alone
or with PHA (7.5 mg/ml). After 48 hr, cells were reisolated Pretreatment of PBMCs with neuraminidase estab-
lished permissivity for growth of HIV-1. PBMCs were pre-in a density gradient of LSM, density 1.077 g/ml, and
were washed twice. After resuspension of cells in RPMI treated with NANase or PHA, or were mock-treated, and
were subsequently exposed to HIV-1IIIB at concentrations1640 at 80 1 106 cells/ml, sialidase activity was assayed
by incubating intact cells for 2 hr at 377 with neuraminyl- ranging from 50 to 1 TCID50 per culture. Viral growth
occurred repeatedly in cells under all three conditionslactose (1 mg/ml) (Sigma). Sialidase activity was deter-
mined by correlating the amount of sialic acid released after infection with 5 or greater TCID50 of HIV-1IIIB (Experi-
ment I, Table 1). A different result was obtained thoughby intact cells to a standard curve generated by determi-
nation of sialic acid released from neuraminyl-lactose by when cells were infected with lesser concentrations of
virus. Exposure of NANase- and PHA-treated PBMCs toserial dilutions of NANase.
Analysis by flow cytometry. PBMCs were PHA-, 1 TCID50 of HIV-1IIIB resulted in productive infection in at
least 50% of wells when assayed up to 21 days afterNANase-, or mock-treated and maintained in culture as
indicated above. Prior to analysis, cells were suspended infection. In contrast, mock-treated PBMCs failed to pro-
duce detectable levels of p24 Ag or RT activity whenin RPMI 1640 at 2 1 107 cells/ml and were incubated for
30 min at 47 with human immunoglobulin (Sandoglobin, similarly infected. Similar results were obtained in mono-
cyte-depleted PBMCs which were NANase-, PHA-, orSandoz Ltd., Basel, Switzerland) at a final concentration
of 0.24% to minimize nonspecific binding of reagents. Cells mock-treated (Experiment II, Table 1). These results were
reproduced with cells from four different donors and twowere double-stained, following the procedure recom-
mended by the manufacturer, with fluorescein isothiocya- different preparations of HIV-1IIIB .
To quantitate the increased permissivity for growth ofnate (FITC)- or phycoerythrin (PE)-conjugated monoclonal
antibodies to CD3 (Leu-4), CD4 (Leu-3), CD8 (Leu-2), CD14 HIV-1 in monocyte-depleted PBMCs resulting from pre-
treatment with NANase, data from multiple experiments(Leu-M3), CD45 (HLE-1), CD57 (Leu-7), and isotypic con-
trols (IgG1 and IgG2) (Becton–Dickinson Monoclonal Cen- similar to Experiment II, Table 1, were evaluated by a
computer program used to determine the absolute titerter, San Jose, CA). Alternatively, cells were left unstained
and were used as controls. Following a 30-min incubation of a stock preparation of virus (Layne et al., 1989; Spouge,
1992). This program calculates virus titer from the num-at 47, cells were washed several times and fixed with 0.5%
formaldehyde. Two-color fluorescence was analyzed with ber of replicate cell cultures which supported growth of
HIV-1 at multiple fourfold dilutions of the inoculum stocka FACScan flow cytometer (Becton–Dickinson, Mountain
View, CA), using a lymphocyte gate as determined by light virus. Relative to the adjusted log10 titer of 1 for the stock
virus when titered in mock-treated cells, the titer wasscatter and staining with CD45 and CD14 antibodies.
Determination of DNA synthesis. PBMCs were treated consistently raised 1.1 to 1.4 { 0.18 log10 when virus
was assayed in cells pretreated with 0.01 to 1.0 U/ml ofwith PHA (1 mg/ml) or NANase (1 U/ml) for 30 min at 377,
or were mock-treated, and were dispensed in 96-well NANase (P  0.01) (Table 2). The titer was similarly
raised by 1.5 to 1.75 { 0.18 log10 in PHA-treated cells.microtiter plates at 1 1 105 cells/well for labeling with
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TABLE 2 fected with serial fourfold dilutions of HIV-191/US/056 , rang-
ing from 64 to 1 TCID50 per culture. Growth of virus wasRelative Rise in Titer of HIV-1 Stock Virus after Pretreatment
detected on Day 7 in two of three cultures of NANase-of Monocyte-Depleted PBMCs with NANase or PHA
treated cells after infection with 4 TCID50 of HIV-191/US/056 ;
Relative titer log10 of HIV-1 in cells pretreated with in contrast, p24 Ag was detected in mock-treated cells on
Day 7 only after infection with 64 TCID50 of HIV-191/US/056Expt None PHA NANase
(Table 3). Virus growth was detected on Day 12 in mock-
treated cells infected with 4 TCID50 of HIV-191/US/056 , butI 1.0 { 0.26 2.519 { 0.18 2.402 { 0.18a
II 1.0 { 0.17 2.747 { 0.18 2.397 { 0.36a the number of cultures with detectable viral growth (one
2.226 { 0.18b of three) and the amount of p24 Ag produced (11.8 ng/
III 1.0 { 0.18 NDc 2.122 { 01.8d ml) were markedly less than that of NANase-treated cells
similarly infected (three of three positive cultures; averageNote. Pretreatment of monocyte-depleted PBMCs with NANase or
p24 Ag of 423.8 ng/ml). The absolute titer of HIV-191/US/056PHA, infection with HIV-1, and evaluation of p24 antigen released into
the medium were described in the note to Table 1. Each experiment in NANase-treated cells on Day 7 was 8.0 1 103/ml; in
was performed with cells from a different donor. The number of positive contrast, the titer in mock-treated cells was 8.0 1 102/ml.
cultures at serial fourfold dilutions of inoculating virus was used to deter- This represented a 1.0 { 0.16 log10 increase in titer of themine a titer in PHA-, NANase-, and mock-treated cells as discussed in
stock solution of HIV-191/US/056 in NANase-treated PBMCsthe text. The absolute titer from mock-treated cells was normalized to 1
compared to the titer in mock-treated cells. The numberto simplify comparisons with the titer in PHA- and NANase-treated cells.
The absolute titers of HIV-1IIIB in mock-, NANase-, and PHA-treated cells of NANase- and mock-treated cultures which were posi-
in one representative experiment (Experiment I) were 6.4 1 102, 2.26 1 tive for viral growth on Day 12 was unchanged after 20
104, and 3.04 1 104, respectively. days in culture (data not shown). Thus, as was found witha NANase, 1 U/ml.
infection by HIV-1IIIB , monocyte-depleted, NANase-treatedb NANase, 0.01 U/ml.
PBMCs were more permissive for infection by the primaryc Not determined.
d NANase, 0.1 U/ml. isolate HIV-191/US/056 than were mock-treated cells.
Pretreatment of PBMCs for 30 min with NANase at 1,
0.1, 0.01, and 0.001 U/ml removed 36 { 3, 28 { 1, 19Similar results from multiple experiments using cells
{ 1, and 12 { 1% of cellular sialic acid, respectively.from different donors and two different virus preparations
Removal of 19% of sialic acid from PBMCs by treatmentwere obtained and used to calculate the reported en-
with 0.01 U/ml of NANase was sufficient to create condi-hancement of viral titer in Table 2. These data support
tions permissive for viral growth (Table 2). PHA-treatedthe finding that pretreatment of monocyte-depleted
PBMCs expressed increased neuraminidase activity,PBMCs with NANase rendered cells permissive for
equivalent to 1.5 { 0.014 mU of NANase per 107 cells,growth of HIV-1IIIB at low m.o.i. at which growth of HIV-
with a concomitant loss of 25% of cell-associated sialic1 consistently remained undetectable in mock-treated
acid. Thus, pretreatment of PBMCs with either PHA orcells.
NANase resulted in hyposialylation of cells.To determine whether NANase treatment of PBMCs
Specific inhibition and heat inactivation of NANase ab-also enhanced growth of primary viral isolates, NANase-
and mock-treated, monocyte-depleted PBMCs were in- rogated its viral growth-promoting action. The specificity
TABLE 3
Pretreatment of PBMCs with Neuraminidase Enhances Susceptibility to Infection with a Primary Isolate of HIV-1
Number of positive cultures after pretreatment with
Control NANase
HIV-1 inoculum
TCID50 Days postinfection 7 12 7 12
64 2/3a (2)b 3/3 (641.2) 3/3 (13.1) 3/3 (1291.5)
16 0/3 — 3/3 (7.0) 2/3 (8.1) 3/3 (605.4)
4 0/3 — 1/3 (11.8) 2/3 (8.0) 3/3 (423.8)
1 0/3 — 0/3 — 0/3 — 1/3 (0.4)
Note. Monocyte-depleted PBMCs were treated with NANase (1 U/ml), or were mock-treated, and were plated at 1 1 105 cells/well and infected
with serial fourfold dilutions of HIV-191/US/056 as described under Materials and Methods. Levels of p24 antigen in culture fluids were determined
by ELISA and data from Days 7 and 12 postinfection are shown. p24 levels 0.015 ng/ml indicated absence of productive infection. The titer of
the inoculum was determined originally in PHA-treated cells.
a Number of wells positive for p24 Ag/number of wells sampled.
b Average amount of p24 (ng/ml) in positive wells.
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TABLE 4
Specificity of NANase-Promoted Growth of HIV-1 in PBMCs
Number of positive cultures
Conditions for NANase pretreatment
of PBMCs Day 12 Day 22
Untreated 0/4a 0/4
NANase, 1 U/ml 3/4 3/4
NANase, 1 U/ml / NeuAc2en (250 mM) 0/4 0/4
Heat-inactivated NANaseb 0/4 0/4
Note. PBMCs were treated with NANase under the indicated conditions and infected with HIV-1 at 1 TCID50 per 2.5 1 105 cells. Growth of infected
cells and determination of p24 antigen levels were as described in the note to Table 1. Heat inactivation of NANase was at 1007 for 5 min. NANase
was exposed to NeuAc2en at 250 mM for 10 min at room temperature prior to pretreatment of cells with the inhibited enzyme. Both NANase and
inhibitor were removed as described under Materials and Methods prior to infection of PBMCs. Virus-producing cultures of NANase-treated PBMCs
produced an average of 59 { 21 and 31 { 18 ng/ml of p24 antigen, respectively, on Days 12 and 22 postinfection.
a Number of wells positive for p24 Ag/number of wells sampled.
b NANase treated at 1007 for 5 min.
of NANase activity was confirmed by inactivation of NAN- in the medium of mock-treated cells infected with 0.5
TCID50 of HIV-1IIIB .ase with a specific inhibitor or after heat treatment. 2,3-
Dehydro-2-desoxy-N-acetyl-neuraminic acid (NeuAc2en) Treatment of PBMCs with NANase did not alter the
is a specific, competitive inhibitor of many neuramini- relative distribution of lymphocyte subsets nor increase
dases, including the NANase used in these experiments expression of cell surface CD4 antigen. To determine if
(Veh and Schauer, 1978; Usuki et al., 1988; Van der Horst NANase pretreatment induced growth of HIV-1 by en-
et al., 1990). Detectable growth of HIV-1 did not occur riching for CD4/ cells, a known target for HIV-1, or by
when PBMCs were treated with NANase in the presence reducing the relative number of CD8/ cells, reported to
of 250 mM NeuAc2en and subsequently infected with 1 inhibit viral growth in CD4/ cells (Walker et al., 1986;
TCID50 of HIV-1, after removal of the NANase and NeuA- Kannagi et al., 1990), the distribution of T cell subsets
c2en (Table 4). This result differs from the viral growth after NANase treatment was analyzed by flow cytometry.
seen in NANase-treated cells when the enzyme was not No significant differences nor any trends in the relative
exposed to inhibitor. To ascertain that NeuAc2en alone
did not nonspecifically inhibit growth of virus, NeuAc2en
(250 mg/ml) was added to cultures of mock-treated cells
infected with 50 TCID50 of virus and maintained in the
medium for the duration of culture. When infected with
this high m.o.i. of HIV-1, mock-treated cells supported
viral growth (Table 1). There was no inhibitory effect on
p24 production under these conditions (data not shown).
Heating of the NANase preparation for 5 min at 1007
destroyed its ability to promote growth of HIV-1 in PBMCs
infected at low m.o.i. This result dismissed the possibility
that the activity reported in Tables 1–3 was heat-stable,
such as expected for endotoxin.
Kinetics of viral growth in NANase-treated cells was
similar to that in PHA-treated cells. The exponential
growth of HIV-1IIIB in NANase-treated cells infected with
0.5 TCID50 of HIV-1IIIB occurred earlier than that in PHA-
treated cells in three experiments (Fig. 1), and simultane-
ously with that in PHA-treated cells in two additional
experiments. That the amount of p24 antigen released FIG. 1. Growth curve of HIV-1 in NANase-treated PBMCs. Pretreat-
ment of PBMCs with NANase for 30 min at 1 U/ml or with PHA, infectioninto the medium was indicative of mature virus was con-
with 0.5 TCID50 HIV-1, maintenance of infected cells in wells of microti-firmed by analyzing identical samples for reverse tran-
ter plates, and assay for p24 antigen were as described in the legendscriptase (RT) activity (Gendelman et al., 1990). Through
to Table 1 and under Materials and Methods. Identical aliquots were
21 days of culture, the level of p24 antigen released was assayed for RT. Data for each time point represent the averages of
highly correlated with the level of RT activity (r  0.88, P eight wells. Mock-treated cells, l; PHA-stimulated cells, h; NANase-
treated cells, j. 0.001). No RT activity nor p24 antigen was detected
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TABLE 5
Pretreatment of PBMCs with NANase Does Not Alter the Relative Distribution of T Cell Subsets
Relative distribution of PBL subsetsa
CD3 CD4 CD8
Treatment Days 0 7 0 7 0 7
None 80 80 58 67 23 13
PHA 82 97 53 68 20 27
NANase 70 71 55 63 19 12
Note. PBMCs were treated for 30 min with NANase at 1 U/ml or with PHA as described in the note to Table 1 and were analyzed by flow
cytometry either immediately after treatment or after 1 week in culture. Staining with monoclonal antibodies, fixation, and analysis by flow cytometry
were as described under Materials and Methods. Unstained cells and cells stained with isotypic (IgG1 or IgG2) antibody were included as negative
controls.
a Percentage of total lymphocytes.
number of cells expressing CD4 or CD8 antigens were synthesis of DNA above levels in mock-treated cells, the
amount of [3H]thymidine incorporated into DNA and thefound between NANase-, PHA-, or mock-treated cells
directly after treatment (Table 5). After 7 days in culture, growth in culture size of mock-, NANase-, and PHA-
treated cells were compared. When grown in the pres-the relative percentage of cells expressing CD4 antigen
under all conditions remained similar. The percentage ence of NHS and rhIL-2, cultures of mock-treated PBMCs,
which did not support the growth of HIV-1 when infectedof T lymphocytes in PHA-stimulated cultures increased
from 82 to 97% after 7 days, whereas there was little at a low multiplicity, and of NANase-treated cells, which
did, incorporated similar amounts of [3H]thymidine intochange in NANase- and mock-treated cultures. The rela-
tive percentage of CD8/ cells in both NANase- and DNA on Days 3, 6, and 9 (Table 7). Similar amounts of
DNA were synthesized under both conditions on Days 1mock-treated cultures declined similarly after 7 days in
culture but increased in PHA-stimulated cultures. These and 2 (data not shown). On each day of analysis, NAN-
ase- and mock-treated cultures incorporated from 15 todata show that the ability of HIV-1 to grow in NANase-
treated cells, but not in mock-treated cells, was not re- 40% of the amount of [3H]thymidine into DNA as did PHA-
treated cells. During the 9 days of observation, the num-lated to differences in the relative distribution of lympho-
cyte subsets. ber of cells in NANase- and mock-treated cultures re-
There remained the possibility that NANase treatment
caused increased expression of CD4 antigen per cell,
TABLE 6thereby facilitating attachment of HIV-1 to CD4/ cells.
Pretreatment of PBMCs with NANase Does Not Alter Cell SizeThe mean channel fluorescence of CD4 antigen per cell
or Relative Expression of Surface CD4(MC-CD4) was the same in NANase- and mock-treated
cells initially and after 7 days in culture (Table 6). In
Relative CD4 expression and cell size
addition, the relative sizes of NANase- and mock-treated
cells, as determined by forward angle light scatter (MC- MC-CD4a MC-FSCb
FSC) during flow cytometry, were similar (Table 6). Imme-
Treatment Days 0 7 0 7diately after treatment, both NANase- and mock-treated
PBMCs were approximately 30% smaller and expressed
None 45 115 111 140
less cell surface CD4 antigen than PHA-treated cells; PHA 56 114 160 158
after 7 days in culture, though, the size and CD4 antigen NANase 47 112 108 146
expression of NANase- and mock-treated cells increased
Note. Cells were treated with NANase or PHA and prepared forto approximately the same values as for PHA-treated
analysis by FACS as described under Materials and Methods and incells. This similarity between NANase- and mock-treated
the note to Table 5. List mode data acquired for the analysis of relative
cells with respect to CD4 antigen expression and cell T cell subsets were reanalyzed by gating on lymphocytes and determin-
size suggested that NANase treatment did not mediate ing the FITC fluorescence parameter (MC-CD4) on CD4-stained cells,
which is proportional to the number of monoclonal antibody bindingits effect by increasing the cell surface density of the
sites per cell, and the mean channel of intensity for the forward scatterCD4 receptor.
parameter (MC-FSC) on unstained cells, which is proportional to cellNANase pretreatment of PBMCs did not promote viral
size. Results are from one experiment which is representative of three
growth by stimulating DNA synthesis. To determine similar experiments.
whether treatment of PBMCs with NANase was mito- a Mean channel fluorescence of CD4/cell.
b Mean channel forward scatter/cell.genic, and thus promoted growth of HIV-1 by stimulating
AID VY 8373 / 6a28$$$501 01-16-97 21:57:08 vira AP: Virology
129ENHANCED GROWTH OF HIV-1 IN NANase-TREATED PBMCs
TABLE 7
NANase Pretreatment of PBMCs Does Not Stimulate Synthesis of DNA nor Promote Cell Division
[3H]Thymidine incorporated (cpm) in cells after treatment with
Days None PHA NANase
3 1,579 { 215 (5.7)a 10,544 { 2,478 (6.9) 1,665 { 466 (5.6)
6 16,894 { 2,012 (5.9) 42,122 { 6,975 (8.8) 13,106 { 2,154 (4.6)
9 23,621 { 4,576 (5.0) 62,953 { 26,711 (20.4) 24,066 { 9,483 (4.4)
Note. PBMCs were treated with PHA (1 mg/ml) or NANase (1 U/ml) for 30 min at 377, or were mock-treated, and were maintained in culture and
assayed for [3H]thymidine incorporation as described under Materials and Methods. Cells were pulsed with 0.50 mCi [3H]thymidine/well for 6 hr on
Days 1, 2, 3, 6, and 9. Data shown for Days 3, 6, and 9 represent an average from five wells prepared and processed identically. A replicate plate
was used for counting cell number and determining viability (five wells/condition) using trypan blue dye exclusion.
a Number of viable cells 1 104/well.
mained similar and relatively constant, whereas the num- growth cycle on events or pathways in CD4/ T lympho-
ber of PHA-treated cells had increased about threefold. cytes which are induced by mitogenic stimulation is not
These results indicate that NANase treatment of PBMCs well understood. It has been shown that PHA activation
under our conditions was not mitogenic; the amount of of PBMCs overcomes a block in reverse transcription of
DNA synthesis and total number of cells through 9 days HIV genomic RNA in quiescent cells (Zack et al., 1990,
in culture were similar to those values in mock-treated 1992). This allows for the synthesis of full-length double-
cells. Thus, the enhancement of viral growth in NANase- stranded viral DNA and viral growth. In addition, cell
treated cells was likely not due to an increase in DNA activation is associated with production of cytokines
synthesis above the level which occurred in mock- which support viral growth (Kinter et al., 1995).
treated cells grown similarly. For the studies in this report, we selected PBMCs
whose baseline level of activation was minimal when
DISCUSSION grown in rhIL-2-deficient medium (see Materials and
Methods). When these unstimulated cells were grownWe have shown in this report that desialylation of gly-
in medium containing rhIL-2, they synthesized moderatecoconjugates on the surface of PBMCs enhanced growth
quantities of DNA (Table 7), but failed to support viralof both T cell line-adapted and primary strains of HIV-1
growth when infected with a low multiplicity of HIV-1.when infection was performed in vitro at a low multiplic-
Neuraminidase treatment of PBMCs was not mitogenic;ity. This effect was demonstrated in cultures of both un-
NANase- and mock-treated PBMCs synthesized equalfractionated and monocyte-depleted PBMCs from multi-
amounts of DNA on Days 1, 2, 3, 6, and 9 followingple donors and was abrogated by a specific inhibitor of
treatment. Yet, the enhancement of viral growth in NAN-NANase. The level of enhancement was similar to that
ase-treated cells infected at low multiplicity was compa-observed in PHA-stimulated cells. The potential rele-
rable to that of PHA-activated cells, where DNA synthesisvance of hyposialylation of lymphocytes to growth of HIV-
was far greater than in NANase- or mock-treated cells.1 in vivo follows from the synthesis of several observa-
Neuraminidase treatment of quiescent cells did not en-tions: (i) activated CD4/ T lymphocytes are permissive
hance growth of HIV-1. No p24 Ag was detected in thefor the growth of HIV-1 (Cullen and Greene, 1989; Gowda
medium of these cells grown in the absence of rhIL-2et al., 1989; Zack et al., 1990) and are hyposialylated
for 8 days postinfection (data not shown). These results(Hunig, 1983; Landolfi and Cook, 1986; Stout et al., 1987;
suggest that a moderate amount of DNA synthesis wasTaira and Nariuchi, 1988; Springer, 1990); (ii) the site of
necessary but not sufficient for growth of virus in PBMCsHIV-1 localization in the germinal centers of lymph nodes
infected at low m.o.i. with HIV-1 and that the enhance-from early and intermediate stage patients (Pantaleo et
ment of viral growth in NANase-treated PBMCs mostal., 1993) coincides with the localization of activated, hy-
likely occurred through a mechanism independent of in-posialylated lymphocytes in the lymph nodes of unin-
creased DNA synthesis.fected individuals (Springer, 1990); and (iii) dendritic
The mechanism(s) for enhanced growth of HIV-1 incells, which are hyposialylated in vivo (Boog et al., 1989),
desialylated PBMCs remains to be determined. One pos-appear to play a role in the replication of HIV-1 (Langhoff
sibility involves the nonspecific removal of repulsive neg-et al., 1993; Pope et al., 1994).
ative charge from the cell surface, thereby promotingHIV-1 can enter quiescent primary CD4/ T lympho-
virus–cell interaction. Alternatively, desialylation of spe-cytes, but viral replication has been detected only after
cific targets for HIV-1 on the cell surface may facilitatesubsequent cell activation (Zack et al., 1990; Ramilo et
al., 1993). The dependence of specific steps in the viral viral attachment and/or entry. Host proteins with pro-
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defect of interferon alpha production in human immunodeficiencyposed roles in the virus–cell interaction, such as the
virus-infected monocytes. J. Exp. Med. 172, 1433–1442.LFA-1 and Fc receptors (Takeda, 1988; Hildreth and
Gorczyca, W., Wieczorek, Z., and Lisowski, J. (1989). Cell surface sialic
Orentas, 1989; Homsy et al., 1989), as well as the CD4 acid affects immunoglobulin binding to macrophages. FEBS Lett.
receptor, which interacts with gp120, are known to have 259, 99–102.
Gowda, S. D., Stein, B. S., Mohagheghpour, N., Benike, C. J., and Engle-sialic acid moieties (Takeda, 1987; Carr et al., 1989;
man, E. G. (1989). Evidence that T cell activation is required for HIV-Gorczyca et al., 1989). Finally, desialylation of a regula-
1 entry in CD4/ lymphocytes. J. Immunol. 142, 773–780.tory cell surface glycoconjugate(s) may trigger intracellu-
Hildreth, J. E. K., and Orentas, R. J. (1989). Involvement of a leukocyte
lar events required for the initiation and/or completion of adhesion receptor (LFA-1) in HIV-induced syncytium formation. Sci-
viral replication. The mechanism of NANase-enhanced ence 244, 1075–1078.
Homsy, J., Meyer, M., Tateno, M., Clarkson, S., and Levy, J. A. (1989).growth of HIV-1 most likely is independent of cellular
The Fc and not CD4 receptor mediates antibody enhancement offeatures which distinguish T cell line-adapted and pri-
HIV infection in human cells. Science 244, 1357–1359.mary isolates of HIV-1, such as CD4 receptor depen-
Hunig, T. (1983). The role of accessory cells in polyclonal T cell activa-
dence (Kabat et al., 1994), as desialylation of PBMCs tion II. Induction of interleukin 2 responsiveness requires cell–cell
promoted infection by both HIV-1IIIB and HIV-191/US/056 . contact. Eur. J. Immunol. 13, 596–601.
Kabat, D., Kozak, S. L., Wehrly, K., and Chesebro, B. (1994). DifferencesFurther studies will help to clarify the mechanism of
in CD4 dependence for infectivity of laboratory-adapted and primaryNANase-enhanced viral growth and to determine its in
patient isolates of human immunodeficiency virus type 1. J. Virol. 68,vivo relevance. Additional studies are needed to deter-
2570–2577.
mine whether treatment with NANase enhances uptake Kannagi, M., Masuda, T., Hattori, T., Kanoh, T., Nasu, K., Yamamoto,
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